Financial
Jan. 19, 2023 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022
NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company…
Oct. 28, 2022 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022
NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company…
Jul. 29, 2022 Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary…
Jan. 27, 2021 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020
GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) — Bioasis Technologies Inc.?(TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”),?a?pre-clinical, research-stage?biopharmaceutical company developing its proprietary?xB3 TM?platform?technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,?today announced… Read more »
Oct. 29, 2020 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020
GUILFORD, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »
Oct. 22, 2020 Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research
GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) — Bioasis Technologies, Inc. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need,… Read more »
Jul. 27, 2020 Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending May 31, 2020
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has… Read more »
Jul. 7, 2020 Bioasis Announces Stock Option Grants
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it… Read more »
Jun. 29, 2020 Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »
Jun. 24, 2020 Bioasis Announces Conversion of Debenture Interest Into Equity
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases,… Read more »